うつ病治療薬の世界市場:予測・動向・機会分析~2031

◆英語タイトル:Depression Drugs Market Analysis By Drug Type (Generic Depression Drugs, Branded Depression Drugs), By Drug Class (Serotonin-norepinephrine Reuptake Inhibitors), By Disease (Major Depressive Disorder, Generalized Anxiety Disorder), By Distribution Channel - Regional Forecast 2031

Future Market Insightsが発行した調査報告書(FMI22FB116)◆商品コード:FMI22FB116
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2021年11月
◆ページ数:約170
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
(同一法人内共有可)USD8,500 ⇒換算¥1,258,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートでは、世界のうつ病治療薬市場について調査・分析し、序論、仮定、調査手法、エグゼクティブサマリー、市場概要、市場動向、ドラッグクラス別(非定型抗精神病薬、セロトニン-ノルエピネフリン再取り込み阻害薬、選択的セロトニン再取り込み阻害薬、CNS覚醒剤、その他)分析、疾患種類別(大鬱病性障害、統合失調症と双極I型障害(躁うつ病)、SSRI誘発、その他)分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局)分析、地域別分析、競争状況など、以下の項目でご提供いたします。
・序論
・仮定
・調査手法
・エグゼクティブサマリー
・市場概要
・市場動向
・世界のうつ病治療薬市場規模:ドラッグクラス別(非定型抗精神病薬、セロトニン-ノルエピネフリン再取り込み阻害薬、選択的セロトニン再取り込み阻害薬、CNS覚醒剤、その他)
・世界のうつ病治療薬市場規模:疾患種類別(大鬱病性障害、統合失調症と双極I型障害(躁うつ病)、SSRI誘発、その他)
・世界のうつ病治療薬市場規模:流通チャネル別(病院薬局、小売薬局、オンライン薬局)
・世界のうつ病治療薬市場規模:地域別
・競争状況

Depression Drugs Market: Report Scope
A recent study by Fact.MR on the depression drugs market offers a 10-year forecast for 2021 to 2031. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates recent market developments, strategic market growth analysis, market size, category market growths, product approvals, product launches, geographical expansions, and technological innovations associated with depression drugs market!

The study also provides the dynamics responsible for influencing the future status of the depression drugs market over the forecast period. A detailed assessment of value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report.

A list of prominent companies operating in the depression drugs market, along with their product portfolios, enhances the reliability of this comprehensive research study.

Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of depression drugs across the globe.

A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of depression drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.

Key Questions Answered in Report
Which are the most lucrative markets for depression drugs?
Which factors will impact the growth of the market?
How will changing trends impact the strategies of market players?
How can market players capture the low-hanging opportunities across regions?
Which companies are leading the depression drugs industry?
What are the winning strategies of stakeholders in the market?
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of volume (‘000 Units) and value (US$ Mn).

Market estimates at global and regional levels for depression drugs is
available in terms of “US$ Mn” for value and in “‘000 Units” for volume. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar opportunity analysis of all the segments adds prominence to the report.

Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and distribution perspective in the global depression drugs market.

Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the depression drugs market during the forecast period.

Country-specific valuation on demand for depression drugs has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.

Detailed breakup in terms of value and volume for emerging countries has also been included in the report.

Competition Analysis
The report sheds light on leading manufacturers of depression drugs, along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering depression drugs have been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.

Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the depression drugs market.

❖ レポートの目次 ❖

Table of Content
1. Preface

1.1. Market Segmentation

1.2. Key Research Objectives

1.3. Research Highlights

2. Assumptions and Acronyms Used

3. Research Approach & Methodology

3.1. Research Methodology overview

3.2. Project Initiation

3.3. Secondary Research Methodology

3.4. Primary Research Methodology

3.5. Analysis Research Methodology

3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Depression Drugs Market

5. Market Overview

5.1. Overview

5.2. Key Industry Events and Developments

5.3. Global Depression Drugs Market Forecast and Analysis

5.4. Global Depression Drugs Market Outlook

6. Market Dynamics

6.1. Drivers and Restraints Snapshot Analysis

6.2. Drivers

6.3. Restraints

6.4. Opportunities

6.5. Key Trends

6.6. Pipeline Analysis

6.7. Depression Treatment Market Value Chain Analysis

7. Global Depression Drugs Market, by Drug Class

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Global Depression Drugs Market, by Drug Class

7.3.1. Atypical antipsychotics

7.3.2. Serotonin-norepinephrine reuptake inhibitors

7.3.3. Selective serotonin reuptake inhibitors

7.3.4. CNS stimulants

7.3.4. Others (Benzodiazepines and miscellaneous antidepressants)

7.4. Global Depression Drugs Market Share Analysis, by Drug Class

7.5. Global Depression Drugs Market Forecast, by Drug Class

7.6. Global Depression Drugs Market Analysis, by Drug Class

8. Global Depression Drugs Market, by Disease Type

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Global Depression Drugs Market, by Disease Type

8.3.1. Major Depressive Disorder

8.3.2. Schizophrenia and bipolar I disorder (manic depression)

8.3.3. SSRI induced

8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type

8.5. Global Depression Drugs Market Forecast, by Disease Type

8.6. Global Depression Drugs Market Analysis, by Disease Type

9. Global Depression Drugs Market, by Distribution Channel

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Global Depression Drugs Market, by Distribution Channel

9.3.1. Hospital pharmacies

9.3.2. Retail pharmacies

9.3.3. Online pharmacies

9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel

9.5. Global Depression Drugs Market Forecast, by Distribution Channel

9.6. Global Depression Drugs Market Analysis, by Distribution Channel

10. Global Depression Drugs Market, by Region

10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region

10.2. Global Depression Drugs Market Analysis, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Global Depression Drugs Market Forecast, by Region

11. North America Depression Drugs Market Analysis

11.1. Policies and Regulations: U.S.

11.2. Key Findings

11.3. North America Depression Drugs Market Overview

11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class

11.5. North America Depression Drugs Market Forecast, by Drug Class

11.5.1. Atypical antipsychotics

11.5.2. Serotonin-norepinephrine reuptake inhibitors

11.5.3. Selective serotonin reuptake inhibitors

11.5.4. CNS stimulants

11.5.5. Others (Benzodiazepines and miscellaneous antidepressants)

11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type

11.7. North America Depression Drugs Market Forecast, by Disease Type

11.7.1. Major depressive disorder

11.7.2. Schizophrenia and bipolar I disorder (manic depression)

11.7.3. Selective serotonin reuptake inhibitors induced

11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel

11.9. North America Depression Drugs Market Forecast, by Distribution Channel

11.9.1. Hospital pharmacies

11.9.2. Retail pharmacies

11.9.3. Online pharmacies

11.10. North America Depression Drugs Market Value Share Analysis, by Country

11.11. North America Depression Drugs Market Forecast, by Country

11.11.1. U.S.

11.11.2. Canada

11.12. Market Trends North America

12. Europe Depression Drugs Market Analysis

12.1. Policies and Regulations: Europe

12.2. Key Findings

12.3. Europe Depression Drugs Market Overview

12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class

12.5. Europe Depression Drugs Market Forecast, by Drug Class

12.5.1. Atypical antipsychotics

12.5.2. Serotonin-norepinephrine reuptake inhibitors

12.5.3. Selective serotonin reuptake inhibitors

12.5.4. CNS stimulants

12.5.5. Others (Benzodiazepines and miscellaneous antidepressants)

12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type

12.7. Europe Depression Drugs Market Forecast, by Disease Type

12.7.1. Major depressive disorder

12.7.2. Schizophrenia and bipolar I disorder (manic depression)

12.7.3. Selective serotonin reuptake inhibitors induced

12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel

12.9. Europe Depression Drugs Market Forecast, by Distribution Channel

12.9.1. Hospital pharmacies

12.9.2. Retail pharmacies

12.9.3. Online pharmacies

12.10. Europe Depression Drugs Market Value Share Analysis, by Country

12.11. Europe Depression Drugs Market Forecast, by Country

12.11.1. Germany

12.11.2. France

12.11.3. Italy

12.11.4. Spain

12.11.5. U.K.

12.11.6. Rest of Europe

12.12. Market Trends Europe

13. Asia Pacific Depression Drugs Market Analysis

13.1. Policies and Regulations: Asia Pacific

13.2. Key Findings

13.3. Asia Pacific Depression Drugs Market Overview

13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class

13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class

13.5.1. Atypical antipsychotics

13.5.2. Serotonin-norepinephrine reuptake inhibitors

13.5.3. Selective serotonin reuptake inhibitors

13.5.4. CNS stimulants

13.5.5. Others (Benzodiazepines and miscellaneous antidepressants)

13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type

13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type

13.7.1. Major depressive disorder

13.7.2. Schizophrenia and bipolar I disorder (manic depression)

13.7.3. Selective serotonin reuptake inhibitors induced

13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel

13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel

13.9.1. Hospital pharmacies

13.9.2. Retail pharmacies

13.9.3. Online pharmacies

13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country

13.11. Asia Pacific Depression Drugs Market Forecast, by Country

13.11.1. China

13.11.2. Japan

13.11.3. India

13.11.4. Australia & New Zealand

13.11.5. Rest of Asia Pacific

13.12. Market Trends Asia Pacific

14. Latin America Depression Drugs Market Analysis

14.1. Policies and Regulations: Latin America

14.2. Key Findings

14.3. Latin America Depression Drugs Market Overview

14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class

14.5. Latin America Depression Drugs Market Forecast, by Drug Class

14.5.1. Atypical antipsychotics

14.5.2. Serotonin-norepinephrine reuptake inhibitors

14.5.3. Selective serotonin reuptake inhibitors

14.5.4. CNS stimulants

14.5.5. Others (Benzodiazepines and miscellaneous antidepressants)

14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type

14.7. Latin America Depression Drugs Market Forecast, by Disease Type

14.7.1. Major depressive disorder

14.7.2. Schizophrenia and bipolar I disorder (manic depression)

14.7.3. Selective serotonin reuptake inhibitors induced

14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel

14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel

14.9.1. Hospital pharmacies

14.9.2. Retail pharmacies

14.9.3. Online pharmacies

14.10. Latin America Depression Drugs Market Value Share Analysis, by Country

14.11. Latin America Depression Drugs Market Forecast, by Country

14.11.1. Brazil

14.11.2. Mexico

14.11.3. Rest of Latin America

14.12. Market Trends Latin America

15. Middle East & Africa Depression Drugs Market Analysis

15.1. Policies and Regulations: Middle East & Africa

15.2. Key Findings

15.3. Middle East & Africa Depression Drugs Market Overview

15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class

15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class

15.5.1. Atypical antipsychotics

15.5.2. Serotonin-norepinephrine reuptake inhibitors

15.5.3. Selective serotonin reuptake inhibitors

15.5.4. CNS stimulants

15.5.5. Others (Benzodiazepines and miscellaneous antidepressants)

15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type

15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type

15.7.1. Major depressive disorder

15.7.2. Schizophrenia and bipolar I disorder (manic depression)

15.7.3. Selective serotonin reuptake inhibitors induced

15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)

15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel

15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel

15.9.1. Hospital pharmacies

15.9.2. Retail pharmacies

15.9.3. Online pharmacies

15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country

15.11. Middle East & Africa Depression Drugs Market Forecast, by Country

15.11.1. GCC

15.11.2. South Africa

15.11.3. Israel

15.11.4. Rest of Middle East & Africa

15.12. Market Trends Middle East & Africa

16. Competition Landscape

16.1. Competition Matrix

16.2. Depression Drugs Market Share Analysis, by Company

16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

16.3.1. Otsuka Pharmaceutical Co., Ltd.

16.3.1.1. Company Description

16.3.1.2. Financial Overview

16.3.1.3. Recent Developments

16.3.1.4. Strategic Overview

16.3.1.4. SWOT Analysis

16.3.2. Eli Lilly and Company

16.3.2.1. Company Description

16.3.2.2. Financial Overview

16.3.2.3. Strategic Overview

16.3.2.4. SWOT Analysis

16.3.3. Pfizer, Inc.

16.3.3.1. Company Description

16.3.3.2. Financial Overview

16.3.3.3. Strategic Overview

16.3.3.4. SWOT Analysis

16.3.4. AstraZeneca plc.

16.3.4.1. Company Description

16.3.4.2. Financial Overview

16.3.4.3. SWOT Analysis

16.3.5. Novartis AG

16.3.5.1. Company Description

16.3.5.2. Financial Overview

16.3.5.3. Strategic Overview

16.3.5.4. SWOT Analysis

16.3.6. GlaxoSmithKline plc

16.3.6.1. Company Description

16.3.6.2. Financial Overview

16.3.6.3. Strategic Overview

16.3.6.4. Recent Developments

16.3.6.5. SWOT Analysis

16.3.7. Takeda Pharmaceutical Company Ltd

16.3.7.1. Company Description

16.3.7.2. Financial Overview

16.3.7.3. Strategic Overview

16.3.7.4. SWOT Analysis

16.3.8. Sebela Pharmaceutical Inc.

16.3.8.1. Company Description

16.3.8.2. Financial Overview

16.3.8.3. Strategic Overview

16.3.8.3. SWOT Analysis

16.3.9. Allergan USA, Inc.

16.3.9.1. Company Description

16.3.9.2. Financial Overview

16.3.9.3. Strategic Overview

16.3.9.3. SWOT Analysis

16.3.10. Johnson & Johnson

16.3.10.1. Company Description

16.3.10.2. Financial Overview

16.3.10.3. Strategic Overview

16.3.10.4. SWOT Analysis

Table 01: Opportunity Map, by Drug Class, 2021

Table 02: Opportunity Map, by Disease Type, 2021

Table 03: Opportunity Map, by Distribution Channel, 2021

Table 04: Global Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2021–2031

Table 05: Global Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 06: Global Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 07: Global Depression Drugs Market (US$ Mn) Forecast, by Region, 2020–2031

Table 08: North America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 09: North America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 10: North America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 11: North America Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031

Table 12: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 13: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 14: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 15: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 16: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 17: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 18: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 19: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 20: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 21: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031

Table 22: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 23: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 24: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 25: France Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 26: France Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 27: France Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 28: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 29: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 30: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 31: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 32: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 33: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 34: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 35: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 36: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 37: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 38: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 39: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 40: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 41: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 42: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 43: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031

Table 44: China Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 45: China Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 46: China Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 47: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 48: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 49: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 50: India Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 51: India Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 52: India Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 53: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 54: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 55: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 56: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 57: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 58: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 59: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 60: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 61: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 62: Latin America depression drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031

Table 63: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 64: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 65: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 66: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 67: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 68: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 69: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 70: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 71: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 72: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 73: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 74: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 75: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031

Table 76: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 77: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 78: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 79: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 80: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 81: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 82: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 83: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 84: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Table 85: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031

Table 86: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031

Table 87: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031

Figure 01: Global Depression Drugs Market Size (US$ Mn), by Drug Class, 2021 (A)

Figure 02: Global Depression Drugs Market Revenue (%), 2021 (A)

Figure 03: Global Depression Drugs Market Size (US$ Mn) Forecast, 2020–2031

Figure 04: Market Value Share, by Drug Class (2021)

Figure 05: Market Value Share, by Disease Type (2021)

Figure 06: Market Value Share, by Distribution Channel (2021)

Figure 07: Market Value Share, by Region (2021)

Figure 08: Global Depression Drugs Market Value Share, by Valence, 2021 and 2031

Figure 09: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Atypical antipsychotics, 2021–2031

Figure 10: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SNRI, 2021–2031

Figure 11: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SSRI, 2021–2031

Figure 12: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNS stimulants, 2021–2031

Figure 13: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021–2031

Figure 14: Global Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 15: Global Depression Drugs Market Revenue (US$ Mn), by MDD, 2021–2025

Figure 16: Global Depression Drugs Market Revenue (US$ Mn), by Schizophrenia and bipolar I disorder, 2021–2025

Figure 17: Global Depression Drugs Market Revenue (US$ Mn), by SSRI induced, 2020–2031

Figure 18: Global Depression Drugs Market Revenue (US$ Mn), by Others, 2020–2031

Figure 19: Global Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 20: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital pharmacies, 2020–2031

Figure 21: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail pharmacies, 2020–2031

Figure 22: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online pharmacies, 2020–2031

Figure 23: Global Depression Drugs Market Analysis, by Region, 2021 and 2031

Figure 24: North America Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031

Figure 25: North America Depression Drugs Market Value Share, by Drug Class, 2021 and 2031

Figure 26: North America Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 27: North America Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 28: North America Depression Drugs Market Value Share, by Country, 2021 and 2031

Figure 29: Europe Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031

Figure 30: Europe Depression Drugs Market Value Share, by Drug Class, 2021 and 2031

Figure 31: Europe Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 32: Europe Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 33: Europe Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031

Figure 34: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031

Figure 35: Asia Pacific Depression Drugs Market Value Share, by Drug Class, 2021 and 2031

Figure 36: Asia Pacific Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 37: Asia Pacific Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 38: Asia Pacific Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031

Figure 39: Latin America depression drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031

Figure 40: Latin America Depression Drugs Market Value Share, by Drug Class, 2021 and 2031

Figure 41: Latin America Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 42: Latin America Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 43: Latin America Depression Drugs Market Value Share, by Country, 2021 and 2031

Figure 44: Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031

Figure 45: Middle East & Africa Depression Drugs Market Value Share, by Drug Class, 2021 and 2031

Figure 46: Middle East & Africa Depression Drugs Market Value Share, by Disease Type, 2021 and 2031

Figure 47: Middle East & Africa Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031

Figure 48: Middle East & Africa Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031

Figure 49: Depression Drugs Sales Analysis, 2016–2020

Figure 50: Depression Drugs Market Share, by Company, 2021

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ うつ病治療薬の世界市場:予測・動向・機会分析~2031(Depression Drugs Market Analysis By Drug Type (Generic Depression Drugs, Branded Depression Drugs), By Drug Class (Serotonin-norepinephrine Reuptake Inhibitors), By Disease (Major Depressive Disorder, Generalized Anxiety Disorder), By Distribution Channel - Regional Forecast 2031)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆